Lineage Cell Therapeutics Logo
US53566P1093
A2PP89
LCTX.TA

Lineage Cell Therapeutics

Forecast

Buy
  5
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Lineage Cell Therapeutics advances preclinical pipeline and extends cash runway to Q3 2028

    Lineage reported preclinical progress in corneal disease, Type 1 diabetes and hearing-loss programs while Roche and Genentech continue optimizing surgical delivery for lead OpRegen. The OPC1 DOSED study has treated two chronic spinal-cord-injury patients with no unexpected safety issues, though it is not designed to assess efficacy. Lineage highlighted its AlloSCOPE manufacturing platform aimed at scalable allogeneic production and said existing GMP banks have been FDA-cleared and used in OpRegen trials. The company ended Q2 with $50.8 million in cash and marketable securities, extending its expected runway into Q3 2028, and remains eligible for up to $615 million in milestones plus tiered royalties from the Roche/Genentech deal. » More on finance.yahoo.com


  • Lineage Cell Therapeutics reports Q2 profit and extends financing through Q3 2028

    Lineage Cell Therapeutics reported a net profit of $1.5 million in the second quarter of 2026 on revenue that fell to $1.1 million. Cash and marketable securities amounted to $50.8 million as of June 30, which the company says finances operations through the third quarter of 2028. The reported gain was largely non‑cash, stemming from a revaluation of option-related liabilities, while operating activities still showed a loss of $8.9 million. Management emphasizes the “Lineage 3.0” platform strategy and points to ongoing partnerships such as OpRegen with Roche/Genentech, as well as expected pipeline updates before the end of 2026. » More on de.investing.com


  • Lineage Cell Therapeutics files prospectus supplement for stock offering of up to $60 million

    Lineage Cell Therapeutics has filed a prospectus supplement with the SEC for the potential sale of common stock totaling up to $60 million. The shares would be offered from time to time under an existing distribution agreement with B. Riley Securities; the supplement is part of an existing shelf registration (Form S-3). The company emphasized that the notice does not constitute an offer to sell and attached a legal opinion; it also highlighted progress in the OpRegen program with Roche/Genentech and received a buy recommendation from H.C. Wainwright with a $9.00 price target. » More on de.investing.com


  • Lineage Cell Therapeutics withdraws CIRM grant application and plans resubmission

    Lineage Cell Therapeutics withdrew its CLIN2 grant application to the California Institute for Regenerative Medicine after receiving feedback and plans to submit a revised application in the next CIRM cycle in January 2026. CIRM did not identify any specific substantive deficiencies, and the company will continue development activities for OPC1 unchanged. The ongoing DOSED study for OPC1 administration is proceeding as planned. Lineage also reported Q3 results with EPS of -$0.13 (below expectations) and revenue of $3.68 million (above expectations), raised $21 million through an ATM sale, and reported its stock price and market capitalization. » More on de.investing.com


  • Lineage reaches 52-week low at $32.78

    Lineage stock fell to a 52-week low of $32.78 and is currently trading near that level, well below its high of $66.38. Year-to-date the price is down about 41.04%, and it fell 48.21% last year. InvestingPro rates the stock as fairly valued, with analyst price targets ranging from $38 to $70. For Q3 Lineage reported record revenue of $1.37 billion but posted a loss per share and cut its full-year forecast; several banks have lowered price targets or adjusted ratings. Despite the loss, Lineage offers a dividend yield of 6.32%, providing investors with short-term income at increased risk. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2003, Lineage Cell Therapeutics has already paid €0.0651 in dividends. The last payout was in December 2003.

Financials

In the last quarter, Lineage Cell Therapeutics had revenue of €1.27M and net profit of €3.74M

(EUR) September 2026
YoY
Revenue 1.27M 59.64%
Gross profit 1.26M 59.72%
Net profit 3.74M 114.72%
EBITDA 4.34M 117.22%

Fundamentals

Metric Value
Market capitalization
€177.95M
Number of shares
252.95M
52-week high/low
€1.81 - €0.70
Dividends No
Beta
1.69
P/E ratio
-25.56
PEG ratio
-0.15
P/B ratio
2.91
P/S ratio
18.02

Company profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Name
Lineage Cell Therapeutics
CEO
Brian Culley
Headquarters Carlsbad, ca
USA
Website
Sector
Consumer Staples
Industry
Food Products
IPO
03/05/1992
Employees 75

Ticker symbols

Exchange Symbol
Tlv
LCTX.TA
AMEX
LCTX
Frankfurt
BT3.F
Düsseldorf
BT3.DU
🍪

Parqet  uses cookies. Learn more